# KRYSTAL-4 (NCT06875310)

> A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

No report yet. It can be ordered.

- Drugs tested: adagrasib plus pembrolizumab
- Indication: untreated KRAS G12C non-squamous non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06875310
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Mirati Therapeutics Inc.
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: Adagrasib; Pembrolizumab; Carboplatin; Pemetrexed; Placebo; Cisplatin
- Enrollment: 630
- Primary outcome: Progression Free Survival (PFS) as Assessed per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Blinded Independent Central Review (BICR)
- Primary outcome: Overall Survival (OS)

## Indexed commentary on KRYSTAL-4 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X
- 1 podcast episode

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=krystal-4-nct06875310